广州博济医药生物技术股份有限公司 2016 年第一季度报告全文 公司负责人王廷春、主管会计工作负责人欧秀清及会计机构负责人(会计主 管人员)欧秀清声明：保证季度报告中财务报告的真实、完整。 2 广州博济医药生物技术股份有限公司 2016 年第一季度报告全文 广州博济医药生物技术股份有限公司 2016 年第一季度报告 2016 年 04 月 1 广州博济医药生物技术股份有限公司 2016 年第一季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 √ 适用 □ 不适用 单位：元 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 计入当期损益的政府补助（与企业业务密切相关，按照国家统 一标准定额或定量享受的政府补助除外） | 573,930.00 | | | 减：所得税影响额 | 86,089.50 | | | 合计 | 487,840.50 | -- | 对公司根据《公开发行证 ...

Financial Performance - The company's operating revenue for 2015 was CNY 126,626,043.64, a decrease of 11.99% compared to CNY 143,873,596.59 in 2014[18]. - The net profit attributable to shareholders for 2015 was CNY 25,663,774.74, down 32.40% from CNY 37,963,575.57 in 2014[18]. - The net cash flow from operating activities was CNY 1,925,986.28, a significant decline of 92.50% compared to CNY 25,687,786.48 in 2014[18]. - Basic earnings per share for 2015 were CNY 0.2008, a decrease of 47.10% from CNY 0.3796 in 2014[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for 2015 was CNY 3,783,983.93, a decrease from CNY 8,280,387.81 in 2014[21]. - The net cash flow from operating activities was negative CNY 8,120,179.56 in 2015, compared to positive CNY 8,866,190.62 in 2014[21]. - Revenue from clinical research services was CNY 95,920,567.57, accounting for 75.75% of total revenue, with a year-on-year decrease of 9.84%[45]. - Revenue from preclinical research services and independent preclinical R&D decreased by 14.99% and 68.58% year-on-year, respectively[45]. - The gross profit margin for clinical research services was 44.53%, with a decrease of 9.84% in revenue compared to the previous year[57]. Assets and Equity - Total assets at the end of 2015 reached CNY 520,151,941.71, an increase of 67.65% from CNY 310,263,048.17 at the end of 2014[18]. - The net assets attributable to shareholders increased by 98.04% to CNY 432,683,630.01 from CNY 218,483,709.07 in 2014[18]. - The company’s total share capital increased to 133,340,000 shares after a capital reserve conversion in 2015[99]. - The net asset value per share attributable to ordinary shareholders fell from 4.3697 in 2014 to 3.2450 in 2015, a decrease of about 25.7%[139]. - The equity attributable to shareholders increased by 98.04% year-on-year, totaling RMB 432,683,630.01[146]. Research and Development - R&D expenses for 2015 amounted to ¥35,489,953.18, accounting for 55.60% of operating costs, a decrease of 4.23% compared to 2014[60]. - The company has developed five major service platforms for preclinical research, enhancing its capabilities in drug evaluation and development[39]. - The company is committed to enhancing its preclinical research services by improving hardware and software conditions and increasing its capacity for consistency evaluation of generic drugs[85]. - The company has implemented strict standard operating procedures to ensure high-quality research services and rapid problem resolution[37]. Strategic Plans and Market Position - The company plans to strengthen internal management and improve research and development service levels to mitigate risks from policy changes[5]. - The company will enhance project management and collaborate closely with clinical trial institutions to recover project progress[6]. - The company plans to enhance its clinical research services and establish a nationwide monitoring service network, aiming to become a large-scale pharmaceutical research service enterprise with international competitiveness[82]. - The company aims to maintain a stable share price to support its long-term development strategy[106]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[181]. Shareholder and Governance - The company distributed a cash dividend of 0.50 yuan per 10 shares, totaling 6,667,000 yuan for the year 2015, which represents 25.98% of the net profit attributable to shareholders[98]. - The company has committed to not transferring or entrusting the management of its shares for 36 months following its initial public offering[101]. - The company has established a sound governance structure, ensuring compliance with the Corporate Law and the Shenzhen Stock Exchange regulations[191]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[192]. - The company emphasizes investor relations management, utilizing multiple channels for communication and feedback with investors[193]. Risks and Challenges - The company faces risks from policy changes that could impact new drug development and contract fulfillment, potentially affecting revenue[88]. - The company is experiencing project delays due to CFDA's self-inspection and verification work, which may impact its 2016 performance[88]. - The company acknowledges the risk of disputes arising from drug registration applications that may not be approved, affecting its brand image and operations[89]. - The company anticipates a potential decline in R&D investment from domestic pharmaceutical companies, which could impact the number and value of projects it can undertake[93]. Employee and Management Structure - The total number of employees in the company is 420, with 348 in the parent company and 72 in major subsidiaries[186]. - The company has a diverse professional composition, with 241 employees in clinical monitoring, 23 in medical and statistics, 31 in business marketing, 59 in preclinical research, and 66 in management and finance[186]. - The management team emphasized a commitment to sustainability, aiming for a 30% reduction in operational carbon footprint by 2025[183]. - The company has a comprehensive training system that includes various training categories such as corporate culture, technical skills, project management, and management skills[188].

广州博济医药生物技术股份有限公司 2015 年第三季度报告全文 广州博济医药生物技术股份有限公司 Guangzhou Boji Medical & Biotechnological Co., Ltd. 2015 年第三季度报告 2015 年 10 月 1 广州博济医药生物技术股份有限公司 2015 年第三季度报告全文 第一节 重要提示 公司负责人王廷春、主管会计工作负责人欧秀清及会计机构负责人(会计主管人员)欧秀清声明：保证 季度报告中财务报告的真实、完整。 2 广州博济医药生物技术股份有限公司 2015 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 510,919,286.78 | 310,263,048.17 | | 64.67% | | 归属于上市公司普通股股东的股东 | 424,331,425.32 | 218,483,709.07 | ...

Financial Performance - Total revenue for the first half of 2015 was CNY 61,363,567.18, representing a 17.30% increase compared to CNY 52,311,532.08 in the same period last year[16]. - Net profit attributable to ordinary shareholders was CNY 12,377,741.74, up 7.24% from CNY 11,542,019.92 year-on-year[16]. - The operating profit for the same period was 14.12 million yuan, reflecting a growth of 6.22% year-on-year[30]. - Clinical research service revenue increased by 17.90% year-on-year, indicating a positive growth trend[31]. - The total comprehensive income for the period was CNY 13,620,810.61, compared to CNY 11,724,910.47 in the previous period, representing an increase of approximately 16.1%[124]. - The company reported a total comprehensive income of CNY 12,377,000 for the current period, which is a significant increase compared to the previous period[134]. Cash Flow and Liquidity - Net cash flow from operating activities improved significantly to CNY 746,011.06, a 106.78% increase from a negative CNY 11,011,139.57 in the previous year[16]. - Cash inflows from operating activities totaled CNY 66,871,341.22, up from CNY 45,686,649.42, indicating a growth of about 46.3%[127]. - The net cash flow from financing activities surged by 857.12% to ¥189,280,704.00, primarily due to funds raised from the company's IPO[34]. - The cash outflow for investing activities was CNY 2,178,599.02, down from CNY 7,154,739.02, indicating a reduction of approximately 69.5%[128]. - Cash and cash equivalents at the end of the period reached CNY 304,249,711.46, compared to CNY 94,944,285.58 at the end of the previous period, marking an increase of approximately 220.5%[128]. Assets and Liabilities - Total assets increased by 64.81% to CNY 511,356,335.03 from CNY 310,263,048.17 at the end of the previous year[16]. - Total liabilities slightly increased from CNY 91,779,339.10 to CNY 91,958,738.02, a change of about 0.2%[114]. - The company's equity surged from CNY 218,483,709.07 to CNY 419,397,597.01, indicating a growth of approximately 92%[114]. - Accounts receivable increased from CNY 57,084,103.96 to CNY 63,261,298.90, reflecting a growth of approximately 10.3%[111]. - Inventory grew from CNY 36,047,593.47 to CNY 41,945,354.16, marking an increase of about 16.5%[112]. Share Capital and Equity Structure - The company plans to increase its total share capital from 66.67 million shares to 133.34 million shares through a capital reserve transfer, with no cash dividends or bonus shares distributed[5]. - The profit distribution plan for the reporting period includes a capital reserve transfer of 10 shares for every 10 shares held, resulting in a total share capital increase to 133,340,000 shares[60]. - The total number of shares increased from 50,000,000 to 66,670,000 shares following the public offering of 16,670,000 shares on April 24, 2015[95]. - Major shareholder Wang Tingchun holds 38.78% of the shares, totaling 25,855,000 shares[99]. - The total number of shareholders at the end of the reporting period was 9,363[99]. Governance and Compliance - The company is focused on enhancing its governance structure and compliance with legal regulations to improve operational efficiency[32]. - The company has committed to maintaining stable stock prices for three years post-IPO, with specific measures in place to prevent share transfers that could affect control[85]. - The company has established a framework for managing shareholding structures to ensure long-term stability and growth[84]. - The company has committed to not engaging in any competitive activities with its subsidiaries during the tenure of its shareholders[88]. - The company confirmed that there are no false records or misleading statements in its prospectus, taking legal responsibility for the accuracy of the information[86]. Risks and Challenges - The company faces risks related to long-cycle contracts in new drug research, which may impact future revenue and profitability[21]. - The company is facing increased competition from both domestic and international CROs, necessitating improvements in marketing and service levels[26]. Research and Development - Research and development investment rose by 3.47% to ¥3,853,500.66, indicating a continued focus on innovation[34]. - The company received a patent for a traditional Chinese medicine composition for treating depression, enhancing its innovation capabilities[31]. - The company is actively expanding its clinical research services into post-marketing evaluation and international multi-center studies[31]. Audit and Financial Reporting - The semi-annual financial report has been audited and is consistent with the previous annual report[89]. - The audit report issued on August 19, 2015, confirmed a standard unqualified opinion, indicating the financial statements are free from material misstatement[110]. - The financial statements were approved by the board of directors on August 19, 2015[146]. Future Outlook - The company is focused on expanding its market presence and enhancing its research and development capabilities in the biotechnology sector[144]. - The company has plans for future product launches and technological advancements to strengthen its competitive position in the market[144]. - The company aims to improve its operational efficiency and explore potential mergers and acquisitions to drive growth[144].